Global Genomics Biomarkers Market 2017-2021
About Genomics Biomarkers
A measurable DNA and/or RNA characteristic is an indicator of normal biologic processes, pathogenic processes, and/or response to a therapeutic or other interventions. A genomic biomarker can be used for measuring the expression, function, and regulation of a gene. These biomarkers have characteristics of one or more deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA).
Technavio’s analysts forecast the global genomics biomarkers market to grow at a CAGR of 17.59% during the period 2017-2021.Covered in this report
The report covers the present scenario and the growth prospects of the global genomics biomarkers market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of genomic biomarkers.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Genomics Biomarkers Market 2017-2021
Technavio recognizes the following companies as the key players in the global genomics biomarkers market: Roche Diagnostics, Myriad Genetics, QIAGEN, Thermo Fisher Scientific, and Bio-Rad Laboratories.
Other Prominent Vendors in the market are: 23andMe, Aepodia, Almac, AROS Applied Biotechnology, DNAVision, Epigenomics, Epistem, Eurofins Scientific, Foundation Medicine, Genomic Health, Liquid Genomics, New England Biolabs, OriGene, and US Biomarkers.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is expansion of new business models. The evolution of biomarkers into clinical applications has changed the market for drugs and diagnostics. As per the evolving market opportunities, the pharmaceutical and diagnostic industries are opting for new business models. In the pharmaceutical industry, the drug development process, safety, and efficacy can be improved with the help of biomarkers.”
According to the report, one of the major drivers for this market is genomics biomarker-based personalized medicine. The use of high-throughput technologies provides a better understanding of the pathology of many diseases at the molecular level. This increased the development of new molecular-targeted treatments and enabled the discovery of molecular-based biomarkers like genomics biomarkers that are used in clinical studies.
Further, the report states that one of the major factors hindering the growth of this market is delay in time from lab to market. Since the rise of the supposed omics innovation, thousands of putative biomarkers have been distinguished and published, which have drastically expanded the options for growing more viable therapeutics. These opportunities have significant advantages for patients and for the financial matters of healthcare services. There are a number of challenges for bringing the biomarkers from the clinical research lab to the market, which are time consuming.
Roche Diagnostics, Myriad Genetics, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, 23andMe, Aepodia, Almac, AROS Applied Biotechnology, DNAVision, Epigenomics, Epistem, Eurofins Scientific, Foundation Medicine, Genomic Health, Liquid Genomics, New England Biolabs, OriGene, US Biomarkers.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook